Psychopharmacology

, Volume 110, Issue 3, pp 257–264

BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties

  • T. P. Blackburn
  • G. S. Baxter
  • G. A. Kennett
  • F. D. King
  • D. C. Piper
  • G. J. Sanger
  • D. R. Thomas
  • N. Upton
  • M. D. Wood
Original Investigations

DOI: 10.1007/BF02251279

Cite this article as:
Blackburn, T.P., Baxter, G.S., Kennett, G.A. et al. Psychopharmacology (1993) 110: 257. doi:10.1007/BF02251279

Abstract

The novel 5-HT3 antagonist, BRL 46470A (endo-N-(8-methyl-8-azabicyclo [3.2.1]oct-3-yl)2,3-dihydro-3,3 dimethyl-indole-1-carboxamide, hydrochloride), has been investigated in a series of in vitro and in vivo tests, including the effect of the drug in models of anxiolysis. In classical tests for 5-HT3 receptor antagonism, BRL 46470A was shown to antagonise 5-HT3 mediated responses in the guinea-pig ileum [pA2 8.3±0.5, slope 0.98±0.20, mean±SEM (5)], the rabbit isolated heart (pA2 10.1±0.1, slope 1.2±0.2,n=5) and the rat Bezold-Jarisch model (ID50 0.7 µg/kg IV±0.1,n=8), with a long duration of action (>3 h). BRL 46470A selectively displaced [3H]-BRL 43694 from 5-HT3 binding sites in rat brain membranes (Ki 0.32 nM±0.04,n=4) without displacing (at concentrations greater than 1 µM) a wide variety of ligands binding to other neurotransmitter receptors, opioid receptors and to neurotransmitter gated ion channel complexes. In vivo, BRL 46470A showed anxiolytic-like activity in two animal models predictive of antianxiety effects-elevated X-maze and social interaction in rats. In both models, BRL 46470A showed significant activity over a wide dose-range following both oral (0.0001–0.1 mg/kg PO) and systemic administration. The unique level of potency of BRL 46470A was apparent in the rat social interaction test and was shown to be 100 fold more potent than the 5-HT3 receptor antagonist ondansetron, with no evidence of a bell-shaped dose response curve over 4 orders of magnitude. BRL 46470A (0.0001 and 0.01 mg/kg SC) also reduced the anxiogenic effects of m-CPP (1-(3-chlorophenyl) piperazine) in the rat elevated X-maze. BRL 46470A is therefore a chemically novel potent and selective 5-HT3 receptor antagonist with anxiolytic potential and a long duration of action in animal studies.

Key words

Anxiolytic 5-HT3 receptors Social interaction X-maze Bezold-Jarisch reflex BRL 46470A 

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • T. P. Blackburn
    • 1
  • G. S. Baxter
    • 1
  • G. A. Kennett
    • 1
  • F. D. King
    • 1
  • D. C. Piper
    • 1
  • G. J. Sanger
    • 1
  • D. R. Thomas
    • 1
  • N. Upton
    • 1
  • M. D. Wood
    • 1
  1. 1.SmithKline Beecham PharmaceuticalsHarlowUK

Personalised recommendations